Search

Displaying results 4061 - 4070 of 10000 in total
  1. Drug

    EGT-101

    go.drugbank.com/drugs/DB17645
    Experimental

    EGT-101 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the human sulfamidase (SGSH) transgene. … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type A.[L45919]

  2. Drug

    Zalutumumab

    go.drugbank.com/drugs/DB12202
    Investigational

    Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). … Zalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer.

  3. Drug

    BMS-214662

    go.drugbank.com/drugs/DB12234
    Investigational

    BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  4. Drug

    Adinazolam

    go.drugbank.com/drugs/DB00546
    Experimental

    It has never been approved by the FDA for clinical use. … Adinazolam (Deracyn®) is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative, and antidepressant properties.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingSynonyms: 8-Chloro-1-((dimethylamino)methyl)-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
  5. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  6. Drug

    BNC105

    go.drugbank.com/drugs/DB06313
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring
  7. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

    Categories: Heterocyclic Compounds, 1-Ring, Endothelin Receptor Antagonists
  8. Drug

    XL820

    go.drugbank.com/drugs/DB05146
    Investigational

    XL820 is a solid. … growth factor receptor alpha, clinically validated targets implicated in a variety of human cancers.

  9. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

  10. Drug

    MMDA

    go.drugbank.com/drugs/DB01442
    ExperimentalIllicit

    MMDA, or 3-methoxy-4,5-methylenedioxyamphetamine, is a member of the amphetamine drug class with stimulant and psychedelic properties. It also acts as an entheogen and an entactogen.

    Categories: Serotonin 5-HT2 Receptor Agonists, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSynonyms: 3-methoxy-methylenedioxyamphetamine, 5-Methoxy-3,4-methylenedioxyamphetamine